← The library
MariTide
maridebart cafraglutide, researchMetabolic/WeightEvidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
PurposeMetabolic / Weight
MechanismGLP-1 receptor agonist and GIP receptor antagonist antibody-peptide conjugate; dosed monthly or less often
EffectsBlocks GIP rather than agonising it — the opposite approach to tirzepatide
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Batches on filenone
No tested batches on file.
Cautions & interactions
Not FDA-approved; avoid self-administration; unverified sourcing and purity
No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.
CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.